Phase i study of pharmacokinetics, safety and acceptability of a single dose of pretomanid added to an optimized background regimen in children with rifampicin resistant tuberculosis impaact 2034
Ended Awarded Last action
- Contract number
- 75N94022F00002
- Awardee
-
Westat, Inc. UEI NVUWAFWQ57S5
- Awarding agency
-
National Institute of Child Health and Human Development
National Institutes of Health, Department of Health and Human Services
- Obligated
- $299,389
Award facts
- Contract value 100% obligated
- $299,389.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $299,389 |
About this award
The National Institute of Child Health and Human Development (NICHD) awarded a $299,389 cost-plus-fixed-fee delivery order to Westat, Inc. on August 3, 2022, to support a Phase I clinical study examining the pharmacokinetics, safety, and acceptability of pretomanid as an addition to optimized background regimens in children with rifampicin-resistant tuberculosis (IMPAACT 2034). The contract, which extends through June 30, 2026, carries no small business set-aside designation and will be performed in Potomac, Maryland. Westat is a well-established professional services firm headquartered in Rockville, Maryland, with extensive experience conducting research, data collection, analysis, and program evaluation services across federal health agencies including the NIH, CDC, and FDA.
This delivery order falls under NICHD's International and Domestic Pediatric and Maternal HIV and Other Highly Infectious Diseases program, reflecting the agency's focus on addressing critical health challenges in vulnerable pediatric populations. Westat's contract role involves supporting clinical trial activities central to evaluating new tuberculosis treatment options for children in resource-limited settings, aligning with NICHD's mission to improve child health outcomes globally. The company's selection for this work reflects its established capabilities in managing complex, multi-site research initiatives and its track record of supporting high-stakes clinical and epidemiological studies through its existing federal contract vehicles.
Quick answers
Who was awarded contract 75N94022F00002?
75N94022F00002 was awarded to Westat, Inc. by National Institute of Child Health and Human Development (National Institutes of Health) on August 3, 2022.
How much is contract 75N94022F00002 worth?
The government has obligated $299,389 on 75N94022F00002.
Is contract 75N94022F00002 an order under another contract?
Yes. 75N94022F00002 is a delivery order under HHSN275201800001I, an indefinite delivery contract.
Was contract 75N94022F00002 competed?
The extent of competition for 75N94022F00002 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award